Why the study?
The safety and efficacy of Angipure compared with eptifibatide in STE-ACS and high-risk PTCA had not been evaluated.
Does Angipure provide similar safety and efficacy compared to eptifibatide in patients with STE-ACS undergoing high-risk PTCA?
Does Angipure provide similar safety and efficacy compared to eptifibatide in patients with STE-ACS undergoing high-risk PTCA?
Angipure, a novel glycoprotein IIb/IIIa receptor inhibitor, appears to have similar safety and efficacy to eptifibatide in patients with STE-ACS undergoing high-risk PTCA.
Answers are grounded in this paper and cite their sources.
May support Angipure dosing in high-risk PTCA; leaves open need for larger trials to confirm safety versus eptifibatide.
Aim. To study the safety and efficacy of Angipure in acute ST-segment elevation coronary syndrome (STE-ACS) and high-risk percutaneous transluminal coronary angioplasty (PTCA) compared with eptifibatide. Material and methods . The study included 157 patients with STE-ACS. High-risk PTCA included massive or total coronary artery thrombosis, noreflow/slow-reflow phenomenon, and acute stent thrombosis. Fifty-five people received Angipure at a dose of 0,72 mg/kg, 52 — at a dose of 0,40 mg/kg, while 50 patients received eptifibatide (Integrilin). We conducted clinical and laboratory studies, electrocardiography (ECG), coronary angiography. Results. According to the criteria "Frequency and severity of hemorrhagic events, including hemorrhagic stroke", "Frequency, severity of other adverse events", there were no differences in safety between Angipure at doses of 0,40 and 0,72 mg/kg and eptifibatide. Complaints, clinical symptoms, vital signs, complete blood count, biochemical and coagulation tests, ECG in patients of different groups were similar and had unidirectional dynamics. The use of Angipure or eptifibatide was considered effective if no adverse outcomes (death, recurrent acute ischemic event, need for urgent revascularization) were observed within 30 days. There were no lethal outcomes. One repeated acute ischemic event was registered in each group. In groups of patients receiving Angipure 0,40 mg/kg and eptifibatide, urgent revascularization was required once each. Conclusion. Angipure and eptifibatide have similar safety and efficacy.
No takes yet. Share an insight, caveat, or question.
Lukyanov et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: